ESMO Immuno-Oncology Congress 2022

Search results (12)

Lung and other thoracic tumours

8 Dec 2022

Two studies explore new predictive biomarkers for immunotherapy in NSCLC

Read more

Precision oncology

8 Dec 2022

Combined biomarker analysis shows promise as a tissue agnostic response predictor for immunotherapy-based treatment

Read more

Lung and other thoracic tumours

7 Dec 2022

Neoadjuvant camrelizumab plus chemotherapy improves pathologic complete response in stage IIIA and B NSCLC

Read more

Lung and other thoracic tumours

7 Dec 2022

Positive preliminary results for combination therapy with adagrasib in KRAS G12C-mutated NSCLC

Read more

Cancer Immunology and Immunotherapy

8 Dec 2022

Preliminary activity is reported with an anti-IL-8 monoclonal antibody plus nivolumab in melanoma

Read more

Cancer Immunology and Immunotherapy

8 Dec 2022

Do immune checkpoint inhibitors affect COVID-19 severity?

Read more

Cancer Immunology and Immunotherapy

7 Dec 2022

Nina Bhardwaj receives the ESMO Immuno-Oncology Award 2022

Read more

Cancer Immunology and Immunotherapy

7 Dec 2022

Is combining radiotherapy and immunotherapy a viable treatment option?

Conflicting clinical results on the benefits of combined radiotherapy and immunotherapy may derive from differences in treatment sequencing  

By Jean-Pascal Machiels

Read more

Cancer Immunology and Immunotherapy

7 Dec 2022

Is there still a future for cancer vaccines?

Despite generally disappointing clinical trial results, technological innovations mean that realising the potential for cancer vaccines could be just around the corner

By Stephen P. Schoenberger

Read more

Cancer Immunology and Immunotherapy

7 Dec 2022

Back to basics: do we need more immuno-oncology in the core curriculum?

By
• Alessandra Curioni Fontecedro

Read more